# a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

> **NCT06166836** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **InxMed (Shanghai) Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** D1553
- **DRUG:** IN10018（Ifebemtinib）

## Key facts

- **NCT ID:** NCT06166836
- **Lead sponsor:** InxMed (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06166836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06166836, "a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06166836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*